What is the level of liabilities of Chimerix this year?
Chimerix has a debt balance of 19.75 M USD this year.
Chimerix Liabilities 2024
Chimerix Liabilities
19.75 M USD
Ticker
CMRX
ISIN
US16934W1062
WKN
A1T65B
In 2024, Chimerix's total liabilities amounted to 19.75 M USD, a -12.24% difference from the 22.5 M USD total liabilities in the previous year.
Chimerix Aktienanalyse
What does Chimerix do?
Chimerix Inc is a biopharmaceutical company focused on the development of antiviral drugs. The company was founded in 2002 and is headquartered in Durham, North Carolina. The history of Chimerix dates back to the research of Dr. George Painter, a renowned scientist in the field of antiviral therapy. He discovered that a certain group of molecules, known as nucleoside analogues, have antiviral properties. The idea was to use these molecules as a starting point for the development of drugs that specifically target viruses. The core idea of Chimerix was to create a new business model that is different from traditional pharmaceutical companies. Instead of focusing on the lengthy and costly development of new compounds, the company wanted to utilize existing molecules and create new drugs through targeted modifications. This approach was not only expected to be faster and cost-effective but also to offer higher chances of success. Chimerix is divided into several business segments. The most important segment is antiviral therapy, where the company focuses on developing drugs against various viruses such as Cytomegalovirus (CMV), Adenovirus, and Herpesvirus. Another business segment of Chimerix is oncology. Here, the company also relies on modifying existing compounds to develop new and effective cancer drugs. One promising molecule currently being developed is Brincidofovir, which not only has antiviral properties but also possesses antitumor properties. In addition to drug development, Chimerix also offers support for clinical trials. The company collaborates with various research institutions and biopharmaceutical companies to test the efficacy and safety of new compounds. The most well-known product of Chimerix is Brincidofovir. This antiviral drug is currently being tested in clinical trials and has the potential to be used against a range of viruses. Its use is particularly promising in patients undergoing immunosuppressive therapy, such as those after a stem cell transplant. Chimerix aims to develop innovative and effective drugs that help patients overcome serious diseases. With its unique business model and close collaboration with the research community, the company has already made promising progress and is an important player in the field of antiviral therapy and oncology. Chimerix ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing Chimerix's Liabilities
Chimerix's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Chimerix's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing Chimerix's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
Chimerix's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in Chimerix’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about Chimerix Stock
What were the liabilities of Chimerix compared to the previous year?
The liabilities of Chimerix have increased by -12.24% dropped compared to the previous year.
What are the consequences of high debt for investors of Chimerix?
High liabilities can pose a risk for investors of Chimerix, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in Chimerix?
Low liabilities mean that Chimerix has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of Chimerix affect the company?
An increase in liabilities of Chimerix can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of Chimerix affect the company?
A decrease in the liabilities of Chimerix can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of Chimerix?
Some factors that can influence the liabilities of Chimerix include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of Chimerix so important for investors?
The liabilities of Chimerix are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can Chimerix take to modify the liabilities?
To change its liabilities, Chimerix can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does Chimerix pay?
Over the past 12 months, Chimerix paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Chimerix is expected to pay a dividend of 0 USD.
What is the dividend yield of Chimerix?
The current dividend yield of Chimerix is .
When does Chimerix pay dividends?
Chimerix pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Chimerix?
Chimerix paid dividends every year for the past 0 years.
What is the dividend of Chimerix?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Chimerix located?
Chimerix is assigned to the 'Health' sector.
Wann musste ich die Aktien von Chimerix kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Chimerix from 6/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/26/2024.
When did Chimerix pay the last dividend?
The last dividend was paid out on 6/26/2024.
What was the dividend of Chimerix in the year 2023?
In the year 2023, Chimerix distributed 0 USD as dividends.
In which currency does Chimerix pay out the dividend?
The dividends of Chimerix are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Chimerix
Our stock analysis for Chimerix Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Chimerix Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
